Mandate

Vinge has advised Stenhus Fastigheter i Norden AB in connection with their uplisting to Nasdaq Stockholm

Vinge has advised Stenhus Fastigheter i Norden AB (publ) (“Stenhus Fastigheter” or the “Company”) in connection with the Company's uplisting to Nasdaq Stockholm. The first day of trading on Nasdaq Stockholm was 18 December 2024.

Stenhus Fastigheter is a real estate company that owns and manages public properties and commercial properties with a clear geographic focus on urban areas and growth cities. Stenhus Fastigheter also works actively with existing and potential building rights within the current portfolio.

Vinge’s team consisted mainly of Rikard Lindahl, Joel Magnusson and Michaela Ådén (Capital Markets and Public M&A), Diana Kanold (VDR), Victor Ericsson, Emelie Svanberg, Marcus Svärd and Ellenor Eckerborn (Tax), Nicklas Thorgerzon and Siri Blomberg (IT och GDPR), Ebba Svenburg and Jonna Skog (Employment), Kristoffer Larson, Madelene Andersson and Sara Franson (Real Estate), Lina Österberg (Environment), Ida Redander, August Ahlin and William Carlberg Johansson (Banking and Finance) and Hayaat Ibrahim and Jonna Fransson (Compliance).

Related

Vinge has advised Oncopeptides in connection with its rights issue

Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025